Matrix metalloproteinases (MMPs) are involved in the normal processes of tissue remodelling and repair, but have increasingly been implicated in a range of disease states where they are over-expressed. This review summarises developments in the design and clinical evaluation of synthetic MMP inhibitors since the subject was last covered in this journal in 1995.
No takes yet. Share an insight, caveat, or question.
R. Paul Beckett (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: